drugset / Trial / NCT05928468
The Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB002
Phase 0
Unknown
210 enrolled
Guangzhou Patronus Biotech Co., Ltd.
Affiliated Hospital of North Sichuan Medical College · collabYantai Patronus Biotech Co., Ltd. · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
To evaluate the safety, humoral immunogenicity, cellular immunogenicity and immune persistence following a heterologous booster dose of recombinant SARS-CoV-2 trivalent vaccine (CHO Cell) LYB002 in Chinese adults 18 years and above completed three-dose Inactivated COVID-19 vaccine;
Timeline
- Start
- 2023-04-25
- Primary completion
- 2023-07-31
- Completion
- 2023-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | LYB002CA | Vaccine | — | Intramuscular |
| Subject | LYB002V14 | Vaccine | — | Intramuscular |
| Comparator | LYB002V14A | Vaccine | — | Intramuscular |